SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of Fortrea Holdings Inc. (NASDAQ: FTRE). The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company’s 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (iii) as a result, the Company’s previously announced EBITDA targets for 2025 were inflated; (iv) accordingly, the viability of the Company’s post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you incurred significant losses and want to act as the lead plaintiff in the class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here: https://www.johnsonfistel.com/investigations/fortrea-holdings-inc

Contact for More Information:
James Baker, (619) 814-4471, jimb@johnsonfistel.com or fjohnson@johnsonfistel.com

Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights:
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Colorado, and Idaho. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, PLLP can help you recover your losses. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.

Achievements:
In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs’ securities law firm in the United States, as determined by the total dollar value of final recoveries.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq.
(619) 814-4471
jimb@johnsonfistel.com or fjohnson@johnsonfistel.com

The post Class Action Filed: Fortrea Holdings Inc. Investors with Losses Urged to Contact Johnson Fistel appeared first on Crypto Insider.

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BigBear.ai Holdings, Inc. (NYSE:BBAI) on behalf of long-term stockholders following a class action complaint that was filed against BigBear on April 11, 2025 with a Class Period from March 31, 2022 through March 25, 2025. Our investigation concerns whether the board of directors of BigBear have breached their fiduciary duties to the company.

The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts regarding BigBear.ai business, operations, and prospects, including allegations that: (i) BigBear maintained deficient accounting review policies related to the reporting and disclosure of certain non-routine, unusual, or complex transactions; (ii) as a result, the Company incorrectly determined that the conversion option within the 2026 Convertible Notes qualified for the derivative scope exception under ASC 815-40 and failed to bifurcate the conversion option as required by ASC 815-15; (iii) accordingly, BigBear had improperly accounted for the 2026 Convertible Notes; (iv) the foregoing error caused BigBear to misstate various items in several of the Company’s previously issued financial statements; (v) as a result, these financial statements were inaccurate and would likely need to be restated; (vi) BigBear would require extra time and expense to correct the inaccurate financial statements, thereby increasing the risk that the Company would be unable to timely file certain financial reports with the SEC; and (vii) as a result, the Company’s public statements were materially false and misleading at all relevant times. 

If you are a long-term stockholder of BigBear, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

The post BIGBEAR ALERT: Bragar Eagel & Squire, P.C. is Investigating BigBear.ai Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm appeared first on Crypto Insider.

SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP, a shareholder rights law firm, announces it is investigating potential breaches of fiduciary duties by certain directors and officers of Masimo Corporation (NASDAQ: MASI) in relation to their obligations to the company’s shareholders.

What can I do? If you are a current Masimo Corporation shareholder, you may have legal claims that may be brought on behalf of the company, against the company’s directors and officers. If you wish to discuss this notice or your legal rights, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

If you have continuously owned MASI shares, you can click or copy and paste the link below in a browser to join: https://www.johnsonfistel.com/investigations/masimo-corporation

What is this about? On or about November 5, 2024, the Court ruled partially granting and partially denying Masimo’s motion to dismiss the shareholder class action lawsuit. The Court permitted claims to proceed against Masimo and its Chief Financial Officer, arising from allegations of inflating Sound United’s financial performance and misleading investors regarding the integration. Concurrently, the Court dismissed claims against other executive defendants.

About Johnson Fistel, PLLP:   Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Colorado, and Idaho. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
jimb@johnsonfistel.com or fjohnson@johnsonfistel.com

The post MASI INVESTIGATION ALERT: Johnson Fistel PLLP Investigates the Directors and Officers of Masimo Corporation for Breach of Fiduciary Duties appeared first on Crypto Insider.

VANCOUVER, British Columbia, June 10, 2025 (GLOBE NEWSWIRE) — Telescope Innovations Corp. (“Telescope Innovations”, “Telescope”, or the “Company”) (CSE: TELI) (OTCQB: TELIF) (FSE:4JU) is a leader in intelligent automation platforms for accelerating chemical process development. The Company announces that it has entered into a secured loan facility with a group of lenders which includes Jason Hein and Henry Dubina, pursuant to which the Company has received a loan (the “Loan”) in the amount of CAD $1,200,000 to support operational activities. The Loan bears interest at a rate of 6.95% per annum and matures on June 1, 2026. Each of Messrs. Hein and Dubina are directors of the Company and are related parties of the Company pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). As a result, the portion of the Loan provided by Messrs. Hein and Dubina, which totals CAD $600,000, constitutes a “related party transaction”. The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to Sections 5.5(a) and 5.7(1)(a) respectively, as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Loan exceeds 25.0% of the Company’s market capitalization.

“This private credit instrument demonstrates the commitment and continued enthusiasm of our founder, board and executive management to accelerate the development of the Company’s Self Driving Laboratory (“SDL”) platforms. We are on the verge of introducing our break-through technology platform to address this completely underserved, rapidly growing market opportunity,” commented Henry Dubina, CEO and Chairman of the Board of Directors of Telescope.

Dr. Jason Hein, Founder and CTO, said, “Our SDL pairs robotics with real-time chemistry analytics and machine-learning-guided experimental loops. The system sets up reactions, measures kinetics on the fly, and decides on the next experiment without researcher slowdown — exactly the automation, data connectivity, and AI foundations that are still lacking as global pharma companies race to modernize their labs. We are accelerating our SDL development efforts precisely when most big-pharma labs are budgeting multi-million dollar upgrades. By acting now, we are positioning Telescope at the forefront of this industry shift.”

The Company paused the previously announced non-brokered private placement equity financing (February 4^th, 2025) due to tariff uncertainty and public market volatility. Currently, private credit offered the optimum flexibility to the Company than traditional commercial credit due to better terms, repayment schedules, covenants, and collateral requirements. As conditions improve, the Company may seek future equity financing as and when the Company needs.

About Telescope Innovations

Telescope Innovations is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.

On behalf of the Board,

Telescope Innovations Corp.

Henry Dubina, Chief Executive Officer 

Forward-Looking Information

Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, and uncertainties that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information.

The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

The post Telescope Innovations’ Directors Establish Private Debt Instrument to Accelerate Development of Self-Driving Labs appeared first on Crypto Insider.

WASHINGTON, June 09, 2025 (GLOBE NEWSWIRE) — Today, Kelly Loeffler, Administrator of the U.S. Small Business Administration (SBA), called on California Governor Gavin Newsom to request an SBA Economic Injury Disaster Loan (EIDL) Declaration to authorize the agency to begin delivering urgent assistance to small businesses across Los Angeles that have been ransacked by rioters since civil unrest began last week. The agency stands ready to deliver critical aid to innocent American victims – whose storefronts have been looted and destroyed by the migrant mob that is wreaking havoc in defense of criminal illegal aliens.

“We’re giving Gavin Newsom the opportunity to stop siding with criminal illegal aliens and start siding with law-abiding Americans – many of whom have lost everything to the violent and destructive riots across Los Angeles,” said SBA Administrator Kelly Loeffler. “The migrant mob has looted stores, destroyed storefronts, and committed criminal acts of vandalism against our small businesses. Although local leaders are allowing Los Angeles to burn, federal partners are ready to help American citizens rebuild – and we will do so, as soon as the Governor answers their call for help.”

For the safety of employees and small business owners, Administrator Loeffler recently announced that SBA would be relocating its Regional Office out of Los Angeles due to the city’s refusal to cooperate with U.S. Immigration and Customs Enforcement (ICE). The Regional Office is located mere steps from the violence that continues to occur in downtown Los Angeles – and where U.S. Marines have been deployed to restore order.

The SBA has provided the state of California with all relevant information needed to request an EIDL Declaration – which will allow small businesses in Los Angeles to apply for low-interest, long-term loans of up to $2 million to help them rebuild following the catastrophic violence of this weekend. Given the urgency of the situation, the SBA is committed to approving any such disaster declaration as soon as it is submitted by Governor Newsom.

The post SBA Administrator Kelly Loeffler Calls on California Governor Gavin Newsom to Request Disaster Declaration for Small Businesses Impacted by L.A. Riots appeared first on Crypto Insider.

SHERIDAN, June 09, 2025 (GLOBE NEWSWIRE) —

Fit Cafe, a wellness-focused brand from Aspen Brass LLC, has updated its official website to share new information about its daily drink powder supplement designed to support clean energy, balanced mood, and metabolic wellness in adults. Now available in the U.S., the plant-based superfood formula offers a simple way to promote daily vitality without added sugar, gluten, or dairy.

According to the official website (www.tryfitcafe.com), Fit Cafe is formulated to align with the body’s natural energy and digestion cycles. The company highlights the supplement’s focus on convenience, offering a quick-to-mix powder that fits easily into a morning routine—no complicated diets or coffee-shop lines required.

“Fit Cafe is about more than just feeling energized—it’s about helping people create a positive, health-forward ritual they actually enjoy,” said a company spokesperson. “Our goal is to simplify wellness through clean, functional ingredients that support how real people live every day.”

Fit Cafe is manufactured in quality-controlled U.S. facilities that adhere to rigorous safety standards. Its blend of superfoods, adaptogens, and nutrients is intended to support natural energy, promote a positive mood, and aid healthy metabolism—making it an ideal choice for individuals seeking a modern wellness solution without stimulants or added sugars.

As noted on the official website, first-time customers are backed by a satisfaction guarantee. Full product details, ingredient information, and direct ordering options are available exclusively at www.tryfitcafe.com.

About Fit Cafe

Fit Cafe is a U.S.-based wellness brand developed by Aspen Brass LLC, offering natural, easy-to-use superfood supplements that support healthy daily routines. Built on a foundation of transparency and simplicity, the brand helps adults feel energized, balanced, and supported—starting with their morning ritual.

Product and Contact Information

Brand: Fit Cafe
Company: Aspen Brass LLC
Website: https://tryfitcafe.com
Email: care@tryfitcafe.com
Phone: 844-240-3279
Mailing Address: 1309 Coffeen Ave, Ste 17470, Sheridan, WY 82801
Return Address: 4711 34th St N Suite F, St. Petersburg, FL 33714

Disclaimer

This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement.

The post Fit Cafe Announces Official Website Update Featuring Natural Daily Supplement for Energy, Mood, and Metabolic Support appeared first on Crypto Insider.

St. Augustine, FL, June 08, 2025 (GLOBE NEWSWIRE) — Florida’s Historic Coast is the place to stay and play this summer and into the Fall with tons of new amenities and adventures to elevate any trip.

New Places to Stay
Now under construction, the AC Hotel St. Augustine by Marriott, situated on the San Sebastian River in St. Augustine’s Historic District, is bringing a thoughtful perspective on luxury. Slated to open this fall, the new space features 142 guest rooms, 1,500 square feet of meeting space, a lounge serving cocktails and a curated menu, the latest in integrated technology, and a 65-slip marina. 

Nestled in the heart of St. Augustine’s historic district, guests at Yalhalla at Griffin Estate, a meticulously restored rental property offers a blend of modern comfort and old-world elegance, featuring a private pool, spa and fire pit, pool table, bar, 4 king suites, and more. Yallaha at Griffin Estate is perfect as a destination for wedding parties and large families looking for luxury enjoy easy access to iconic landmarks, vibrant dining, and shopping.

Fresh Bites
Ragga Surf Cafe has brought its laid-back beach vibe to the San Sebastian Riverfront on Riberia Street. It has fresh, scratch-made breakfast and lunch specialties served alongside specialty coffee drinks.  The Floridian, a pioneer in St. Augustine’s farm-to-table movement, will lose its doors in the Historic District to bring two new wild ideas to life: Bea’s Fine Foods + All Day Café and Jefe’s Fish Wagon. Both will be located on Anastasia Blvd. and are set to open Summer of 2025. Bea’s Fine Food + All Day Café is named after co-owner/chef Genie McNally’s grandmother, Bea’s will be a fun, fresh, and inventive take on some of her favorite things. Jefe’s Fish Wagon will feature fully customizable burritos and sandwiches served up from the brand-new food truck.

Castillo Craft Bar + Kitchen is now home to Executive Chef Donald “Don” Green, whose extensive banquet experience will elevate the Renaissance St. Augustine Historic Downtown’s event and meeting spaces. Meehan’s Irish Pub + Seafood House announced that homegrown Chef Corey Brown will helm the traditional Irish scratch kitchen. Lynda’s at the Ocean Club Restaurant, part of the newly renovated Ponte Vedra Ocean Club, hired Chef Luis Abbey, previously at the Westin Resort in Jekyll Island, GA.

Michael’s is now open in its new coastal location at the Hyatt Place Vilano Beach, where Chef Michael Lugo continues serving his inspired fare, paired with an award-winning wine list. Two new spaces opened in Historic Downtown St. Augustine: Saint and The French Pantry. Saint offers Italian fine dining with a beautiful courtyard and open-air balcony seating right on the bayfront. Recently opened on 36 Granda Collective concepts, featuring The French Pantry, serving French-inspired baked goods and heartier fare, along with Little Miss Ha, La Petite Kitchen, and Cache Cache. Each brings a unique perspective to the shared culinary experience. 

In nearby Hastings, the Hastings Coffee Company has become the place for coffee and community where guests gather and chat over espresso drinks, hand-poured coffees, and locally sourced treats.

Explore and Play
St. Augustine’s Florida Water Tours is welcoming a new boat to its fleet. “Great Blue Heron” will be ready to help passengers discover the real Florida this summer, with ecotours, sunset cruises, wine tastings, and more. Rated for 49 passengers, the family-owned and operated outfit can now accommodate 109 passengers between its three boats. I n Ponte Vedra, TPC Sawgrass has promoted Matt Borocz to General Manager of the expansive Ponte Vedra property, which hosts the international THE PLAYERS Championship and encompasses two world-class golf courses, NINETEEN restaurant, and over 13,000 square feet of banquet and meeting space.

The settlement of Garcia Real de Santa Theresa de Mose, now referred to as Fort Mose Historic State Park, was established in 1738 as the first free black settlement in the United States and was inhabited by former slaves, who escaped through the original Underground Railroad, which flowed from  Georgia and the Carolinas to Spanish St. Augustine. Fort Mose Historic State Park serves as a historical and cultural destination and features a newly opened reconstruction of the fort structure, and after 30 years of work, Fort Mose has once again become a tangible structure. The replica fort, new centerpiece of the park opened in May 2025, and was constructed at a cost of $3 million, raised through grants, donations, and fundraising events like the annual Fort Mose Jazz & Blues Series.  Fort Mose is open Thursday through Monday, from 9 a.m. to 5 p.m. with guided tours of the new fort are at 10 a.m. and 1 p.m.

Concerts at the St. Augustine Amphitheatre just got way cooler, with the addition of The Amp Shop and Box Office, offering exclusive Amphitheatre-branded apparel, collectibles, and in-person concert ticket sales to avoid online ticketing fees. The expansion also includes The Kookaburra Coffee Outpost, a full-service coffee shop offering a comprehensive menu of coffee, espresso, house-made baked goods, and retail coffee products.

August 1, 2025 will mark the reopening of the Ponte Vedra Concert Hall, an indoor live music venue that has undergone an extensive renovation designed to elevate the listener experience. The Hall is hitting the ground running with a full slate of performances, including Dan Tyminski Band, Sister Hazel, and Melissa Etheridge. Tickets for the summer/fall line-up of performers are now on sale.

The rural community of Hastings has added a new piece to its growing public art collection with a mural by Kelsey Montague. Secured through the St. Johns Cultural Council’s Art in Public Spaces grant program the artwork celebrates the area’s rich farming heritage with vibrant imagery of local crops, native wildlife, and an interactive vegetable cart pulled by a real bicycle. And, St. Johns County’s multigenerational Treaty Park is now home to 12 new pickleball courts, bringing the total to 20 courts, making it the perfect location for some friendly competition.

Flights
Getting here is easier with new flight options. Jacksonville International Airport (JAX) now offers nonstop flights to New Castle, Delaware, through Avelo; a route to Austin, Texas, courtesy of Delta Airlines; and Allegiant started direct service to JAX from Des Moines, Iowa, Grand Rapids, Michigan, and Akron-Canton, Ohio. Arajet is expanding into the Orlando market with new nonstop service between Orlando Sanford International Airport and Punta Cana International Airport in the Dominican Republic. In addition to their existing service at JAX, Breeze Airways will begin service between Daytona Beach International Airport and Akron-Canton, Ohio, as well as Ocean City, Maryland, this fall.

Coming with a group or looking for a meeting spot that strikes a balance between work and play? Be sure to download the new Group Travel Guide, the penultimate tool for planning meetings and group events. 

Located midway between Daytona Beach and Jacksonville, Florida’s Historic Coast includes historic St. Augustine, the outstanding golf and seaside elegance of Ponte Vedra, the rural beauty of Hastings, Elkton, St. Johns, and 42 miles of pristine Atlantic beaches. Visitor Information Centers are located at 10 Castillo Drive, St. Augustine; 200 Solana Rd. Suite B, Ponte Vedra Beach: and at the St. Johns County Beach Pier Park, 350 A1A Beach Blvd., St. Augustine Beach. For advance travel information, call 1.800.653.2489 or go to the Visitors and Convention Bureau website at www.FloridasHistoricCoast.com. Check us out on social media Instagram @FloridasHistoricCoast; @ViajaStAugustine,  Facebook.com/OfficialStAugustine, and Facebook.com/ViajaStAugustine and Twitter @FlHistoricCoast

# # #

Attachments

• Hastings farming heritage is celebrated in new mural
• Newly reconstructed Fort Mose

The post Meet What’s New with Florida’s Historic Coast’s New Amenities appeared first on Crypto Insider.

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the firm.

SO WHAT: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Zenas BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=37109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 16, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Registration Statement contained false and/or misleading statements and/or failed to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zenas BioPharma action, go to https://rosenlegal.com/submit-form/?case_id=37109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

The post ZBIO FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – ZBIO appeared first on Crypto Insider.

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color

Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients

Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline

Results support commitment to enhance clinical understanding of chronic diseases in communities of color

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent^® (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. These are the first clinical trial results for Dupixent in a large population of patients with darker skin tones. The results, along with the Dupixent Phase 3 trials, demonstrated patients taking Dupixent experienced improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones. The data were shared in an oral presentation at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.

“Atopic dermatitis, a chronic disease with underlying type 2 inflammation, has a high prevalence and quality of life impact on patients with skin of color. Unique clinical features like darker patches of hyperpigmentation versus redness typically seen on lighter skin may lead to less accurate diagnoses and underestimation of disease severity,” said Andrew Alexis, M.D., M.P.H., Professor of Clinical Dermatology at Weill Cornell Medicine. “The results from the DISCOVER trial showed that Dupixent patients with atopic dermatitis and darker skin not only experienced reduced disease severity and itch but also saw improvements in areas of particular concern including dyspigmentation and dry skin. These data deepen the clinical understanding of atopic dermatitis within this underserved population, including use of newly validated scales.”

In the trial, 120 patients with atopic dermatitis and skin of color (82% Black, 11% Asian, 2% American Indian/Alaska Native, 5% Arab, Central American or other) were treated with Dupixent every two weeks using a weight-based dosing regimen. At 24 weeks:

• 76% achieved a ≥75% improvement in overall disease severity (EASI-75), the primary endpoint. Improvements were seen by some patients as early as two weeks.
• 53% achieved clinically meaningful improvement in itch (≥4-point reduction on the peak-pruritus numerical rating scale [PP-NRS]). Improvements were seen by some patients as early as two weeks.
• Patients experienced a 53% reduction from baseline in post-inflammatory hyperpigmentation, dropping from 5.1 points (moderate/marked) to 2.4 points (mild).
• 18% were very or extremely bothered by dry skin vs. 78% at baseline, based on patient reporting.

The safety results in the DISCOVER trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indications. The overall rate of adverse events (AEs; n=124) in the DISCOVER trial was 42%, with the most common (≥2%) AEs being headache (3%), upper respiratory tract infection (2%), eczema (2%), conjunctivitis (3%) and allergic conjunctivitis (2%).

About Atopic Dermatitis in Skin of Color
Atopic dermatitis is a chronic skin disease with underlying type 2 inflammation that causes intense, persistent itch and skin lesions that cover much of the body, resulting in skin dryness, cracking, pain, crusting and oozing. In patients with skin of color, the type and location of the lesions can vary, and they are more likely to have hardened skin lesions and severe skin dryness, itch, dyspigmentation and greater disease severity than those with lighter skin. Additionally, redness that is observed on lighter skin typically appears as darkened, grey or violet on darker skin tones. Because the disease presents differently in people with skin of color, it can be misdiagnosed or the severity underestimated, which can contribute to higher levels of healthcare resource utilization.

About the DISCOVER Clinical Trial
The DISCOVER Phase 4 open-label, single-arm trial evaluated the efficacy and safety of Dupixent in adults and adolescents aged 12 years and older with moderate-to-severe atopic dermatitis and skin of color, as defined by Fitzpatrick skin types IV-VI (those with high melanin; light brown to black). During the 24-week treatment period, all patients in the trial received Dupixent monotherapy every two weeks based on weight after a loading dose: patients weighing ≥30 to <60 kg received 200 mg and patients weighing ≥60 kg received 300 mg.

The primary endpoint assessed the proportion of patients who achieved at least 75% improvement on the Eczema Area and Severity Index (EASI-75) at 24 weeks. Secondary endpoints included the proportion of patients who achieved ≥4-point improvement on the Peak-Pruritus Numerical Rating Scale (PP-NRS) at 24 weeks. Additional endpoints included pigmentary changes on the clinician-reported Post-Inflammatory Hyperpigmentation Severity Scale (PHSS; scale: 0-8) and skin dryness on the newly developed patient-reported Xerosis NRS (X-AD; scale: 0-10) at 24 weeks.

About Dupixent
Dupixent, which was invented using Regeneron’s proprietary VelocImmune^® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD) in different age populations. More than 1,000,000 patients are being treated with Dupixent globally.¹

About Regeneron’s VelocImmune Technology 
Regeneron’s VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron’s co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite^® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent^® (dupilumab), Libtayo^® (cemiplimab-rwlc), Praluent^® (alirocumab), Kevzara^® (sarilumab), Evkeeza^® (evinacumab-dgnb), Inmazeb^® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz^® (pozelimab-bbfg). In addition, REGEN-COV^® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.

Dupilumab Development Program 
Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. 

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. 

U.S. INDICATIONS 
DUPIXENT is a prescription medicine used:

• to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 months of age.
• with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in adults and children 6 years of age and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. It is not known if DUPIXENT is safe and effective in children with asthma under 6 years of age.
• with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with chronic rhinosinusitis with nasal polyps under 12 years of age.
• to treat adults and children 1 year of age and older with eosinophilic esophagitis (EoE), who weigh at least 33 pounds (15 kg). It is not known if DUPIXENT is safe and effective in children with eosinophilic esophagitis under 1 year of age, or who weigh less than 33 pounds (15 kg).
• to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT is safe and effective in children with prurigo nodularis under 18 years of age.
• with other medicines for the maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD). DUPIXENT is used to reduce the number of flare-ups (the worsening of your COPD symptoms for several days) and can improve your breathing. It is not known if DUPIXENT is safe and effective in children with chronic obstructive pulmonary disease under 18 years of age.
• to treat adults and children 12 years of age and older with chronic spontaneous urticaria (CSU) who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if DUPIXENT is safe and effective in children with chronic spontaneous urticaria under 12 years of age, or who weigh less than 66 pounds (30 kg).

DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine.

DUPIXENT is not used to treat any other forms of hives (urticaria).

IMPORTANT SAFETY INFORMATION

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT^®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

• have eye problems.
• have a parasitic (helminth) infection.
• are scheduled to receive any vaccinations. You should not receive a “live vaccine” right before and during treatment with DUPIXENT.
• are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease, or chronic spontaneous urticaria, and also have asthma. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.

DUPIXENT can cause serious side effects, including:

• Allergic reactions. DUPIXENT can cause allergic reactions that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, joint pain, general ill feeling, itching, skin rash, swollen lymph nodes, nausea or vomiting, or cramps in your stomach-area.
• Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed
• Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. Tell your healthcare provider right away if you have: rash, chest pain, worsening shortness of breath, brown or dark colored urine, persistent fever, or a feeling of pins and needles or numbness of your arms or legs.
• Psoriasis. This can happen in people with atopic dermatitis and asthma who receive DUPIXENT. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination if needed.
• Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.

The most common side effects include:

• Eczema: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, dry eye, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia).
• Asthma: injection site reactions, high count of a certain white blood cell (eosinophilia), pain in the throat (oropharyngeal pain), and parasitic (helminth) infections.
• Chronic Rhinosinusitis with Nasal Polyps: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, high count of a certain white blood cell (eosinophilia), gastritis, joint pain (arthralgia), trouble sleeping (insomnia), and toothache.
• Eosinophilic Esophagitis: injection site reactions, upper respiratory tract infections, cold sores in your mouth or on your lips, and joint pain (arthralgia).
• Prurigo Nodularis: eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, herpes virus infections, common cold symptoms (nasopharyngitis), dizziness, muscle pain, and diarrhea.
• Chronic Obstructive Pulmonary Disease: injection site reactions, common cold symptoms (nasopharyngitis), high count of a certain white blood cell (eosinophilia), viral infection, back pain, inflammation inside the nose (rhinitis), diarrhea, gastritis, joint pain (arthralgia), toothache, headache, and urinary tract infection.
• Chronic Spontaneous Urticaria: injection site reactions.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it’s recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.

Please see accompanying full Prescribing Information including Patient Information.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center^® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

About Sanofi 
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

Regeneron Forward-Looking Statements and Use of Digital Media 
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Dupixent^® (dupilumab); uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as Dupixent for the treatment of chronic pruritus of unknown origin, bullous pemphigoid, lichen simplex chronicus, and other potential indications; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA^® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended March 31, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Sanofi Disclaimers or Forward-Looking Statements 
This media update contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.

¹ Data on File

The post Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color appeared first on Crypto Insider.

NEW YORK, June 07, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Tempus AI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=39867 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On May 28, 2025, before the market opened, Investing.com published an article entitled “Tempus AI stock sinks following Spruce Point short report.” The article stated Tempus AI shares had fallen after “the company was targeted in a short-seller report by Spruce Point. The report raised serious concerns about the integrity of Tempus AI’s product, the credibility of its management, and its financial reporting practices.”

On this news, Tempus AI’s stock fell 19.2% on May 28, 2025.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

The post TEM Investor News: If You Have Suffered Losses in Tempus AI, Inc. (NASDAQ: TEM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights appeared first on Crypto Insider.